Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | GLI1 | P08151 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489282 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL7536202 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL1275426 | 0.86 | ALOX15 (0.38) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL285831 | 0.85 | NOS2 (0.37) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL11484027 | 0.85 | NOS2 (0.36) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL11559258 | 0.84 | NOS2 (0.38) | NOS2NOS3NOS1GLI1PRCP | |
| SCHEMBL1537227 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL11858950 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL756555 | 0.84 | SLC7A5 (0.36) | NOS2NOS3NOS1PRCPDPP7 | |
| SCHEMBL51271 | 0.84 | NOS2 (0.36) | NOS2NOS3NOS1GLI1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567559-A | Peptide with anti-forgetting activity and preparation method and application thereof | 安琪生物科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117486971-A | Antioxidant peptide, walnut peptide and preparation method and application thereof | 安琪生物科技有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20210024593-A1 | MODIFIED HEAT SHOCK PROTEINS | RUBICON BIOTECHNOLOGY LLC | 2021-01-28 | — | — | US | disclosed |
| EP-3672985-A2 | MODIFIED HEAT SHOCK PROTEINS | Rubicon Biotechnology LLC (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040887-A2 | MODIFIED HEAT SHOCK PROTEINS | RUBICON BIOTECHNOLOGY LLC (US) | 2019-02-28 | — | — | WO | disclosed |
| US-8044230-B2 | Hydrolytic stability needed to maintain the prodrug in solution in the subject's system until appropriate conditions exist when the prodrug can hydrolyze, releasing the active compound | INTERVET INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20080146640-A1 | Water-Soluble Prodrugs of Chloramphenicol, Thiamphenicol, and Analogs Thereof | SCHERING-PLOUGH LTD. (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2005080551-A2 | STEM CELLS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146640-A1 | Water-Soluble Prodrugs of Chloramphenicol, Thiamphenicol, and Analogs Thereof | TREH, ADH5, CES2 | NOS2 286/4885NOS3 335/4885NOS1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.